ライフサイエンスコーパス: brentuximab vedotin

1 e enrolled and received at least one dose of brentuximab vedotin.

2 e development of the antibody-drug-conjugate brentuximab vedotin.

3 17, a total of 12 patients with LyP received brentuximab vedotin.

4 ther anticancer therapy after treatment with brentuximab vedotin.

5 oth autologous stem-cell transplantation and brentuximab vedotin.

6 isease progressed on or after treatment with brentuximab vedotin.

7 ter autologous stem-cell transplantation and brentuximab vedotin.

8 78% after a relapse following the receipt of brentuximab vedotin.

9 ational design of combination therapies with brentuximab vedotin.

10 consistent with the known safety profile of brentuximab vedotin.

11 A total of 102 patients were treated with brentuximab vedotin 1.8 mg/kg by intravenous infusion ev

12 Intravenous brentuximab vedotin 1.8 mg/kg infused over 30 minutes ev

13 d web response system to receive intravenous brentuximab vedotin 1.8 mg/kg once every 3 weeks, for up

14 Brentuximab vedotin 1.8 mg/kg was administered every 3 w

15 00% CD30 expression levels were treated with brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maxi

16 After brentuximab vedotin, 12 patients (27%, 95% CI 13-40) wer

17 Clinical activity and safety of brentuximab vedotin, a CD30 targeting antibody-drug conj

18 In the present investigation, we evaluated brentuximab vedotin, a CD30-directed Ab-drug conjugate,

19 l study evaluated the efficacy and safety of brentuximab vedotin, a CD30-directed antibody-drug conju

20 r study evaluated the efficacy and safety of brentuximab vedotin, a CD30-directed antibody-drug conju

21 Recently, brentuximab vedotin, a conjugate of an anti-CD30 antibod

22 Brentuximab vedotin, a monoclonal antibody (cAC10) conju

23 s lymphoma patients treated with single-dose brentuximab vedotin, a new anti-CD30 monoclonal antibody

24 ith R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control a

25 es had been taken into account in developing brentuximab vedotin (Adcetris), an ADC that recently rec

26 l study evaluated the safety and activity of brentuximab vedotin administered sequentially with CHOP

27 Brentuximab vedotin, administered sequentially with CHOP

28 Early consolidation with brentuximab vedotin after autologous stem-cell transplan

29 tion of patients who were PET-negative after brentuximab vedotin alone or brentuximab vedotin followe

30 y well tolerated and had activity similar to brentuximab vedotin alone.

31 , open-label study evaluated the efficacy of brentuximab vedotin, an anti-CD30 antibody-drug conjugat

32 lled and randomly assigned to a group (66 to brentuximab vedotin and 65 to physician's choice), with

33 d phase 2 dose was deemed to be 1.8 mg/kg of brentuximab vedotin and 90 mg/m(2) of bendamustine, whic

34 21 (95%) of 22 patients given brentuximab vedotin and ABVD achieved complete remission

35 ured in 41% of all patients (14 [56%] in the brentuximab vedotin and ABVD group and seven [27%] in th

36 ntuximab vedotin and AVD group), and, in the brentuximab vedotin and ABVD group only, pulmonary toxic

37 neutropenia (20 [80%] of 25 patients in the brentuximab vedotin and ABVD group vs 20 [77%] of 26 pat

38 were febrile neutropenia (four [16%] in the brentuximab vedotin and ABVD group vs two [8%] in the br

39 r, an unacceptable number of patients in the brentuximab vedotin and ABVD groups had pulmonary toxic

40 The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for c

41 ABVD group vs 20 [77%] of 26 patients in the brentuximab vedotin and AVD group), anaemia (five [20%]

42 ab vedotin and ABVD group vs two [8%] in the brentuximab vedotin and AVD group), and, in the brentuxi

43 edotin and ABVD group and seven [27%] in the brentuximab vedotin and AVD group).

44 ission, as did 24 (96%) of 25 patients given brentuximab vedotin and AVD.

45 homas have durable responses to single-agent brentuximab vedotin and show longer progression-free sur

46 trials are assessing novel agents, including brentuximab vedotin and the anti-CCR4 antibody, mogamuli

47 h is under way to extend the applications of brentuximab vedotin and to advance the field by developi

48 e two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the f

49 Finally, brentuximab-vedotin and the KIT D816V-targeting drug PKC

50 4 women; median age, 46 years) responded to brentuximab vedotin, and 7 exhibited a complete response

51 ta were consistent with the known profile of brentuximab vedotin, and included at least grade 3 event

52 ither relapsed after or failed to respond to brentuximab vedotin, and with an Eastern Cooperative Onc

53 ience of the German Hodgkin Study Group with brentuximab vedotin as single agent in 45 patients with

54 enter dose-escalation study, we administered brentuximab vedotin (at a dose of 0.1 to 3.6 mg per kilo

55 Brentuximab vedotin before reduced-intensity allo-HCT do

56 omography (PET)-adapted salvage therapy with brentuximab vedotin (BV) and augmented ifosfamide, carbo

57 ot study assessed the safety and efficacy of brentuximab vedotin (BV) and AVD (adriamycin, vinblastin

58 In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administer

59 treatment with the anti-CD30 toxin conjugate brentuximab vedotin (BV) have been associated with remis

60 fficacy of the antibody-drug conjugate (ADC) brentuximab vedotin (BV) in relapsed/refractory peripher

61 Brentuximab vedotin (BV) is an antibody-drug conjugate t

62 2, nonrandomized, open-label study evaluated brentuximab vedotin (BV) monotherapy (results previously

63 nts received doses of 0.6, 0.9, or 1.2 mg/kg brentuximab vedotin by intravenous infusion every 2 week

64 ory Committee for an accelerated approval of brentuximab vedotin by the Food and Drug Administration.

65 ficant proportion of patients who respond to brentuximab vedotin can achieve prolonged disease contro

66 ractory Hodgkin lymphoma who were treated on brentuximab vedotin clinical trials to evaluate the effi

67 1.2 mg/kg brentuximab vedotin combined with AVD given every 2 week

68 We recorded consistent benefit (HR <1) of brentuximab vedotin consolidation across subgroups.

69 In vitro treatment with brentuximab vedotin decreased cell proliferation, induce

70 The antibody-drug conjugate brentuximab vedotin delivers the potent antimicrotubule

71 In phase I studies, brentuximab vedotin demonstrated significant activity wi

72 Brentuximab vedotin demonstrated significant clinical ac

73 Brentuximab vedotin demonstrated the most potent single

74 le ongoing clinical trials are investigating brentuximab vedotin efficacy in other CD30-positive hema

75 Brentuximab vedotin, first in class and gold standard, w

76 PET-adapted sequential salvage therapy with brentuximab vedotin followed by augICE resulted in a hig

77 -negative after brentuximab vedotin alone or brentuximab vedotin followed by augICE.

78 activity of PET-adapted salvage therapy with brentuximab vedotin, followed by augmented ifosfamide, c

79 el, single-center, phase 2 clinical trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas

80 ry approval of ado-trastuzumab emtansine and brentuximab vedotin for clinical use.

81 Responders received single-agent brentuximab vedotin for eight to 10 additional cycles (f

82 ical activity of the recently approved ADCs, brentuximab vedotin for Hodgkin lymphoma and ado-trastuz

83 ese results support the potential utility of brentuximab vedotin for selected patients with HL relaps

84 To assess the efficacy and safety of brentuximab vedotin for the treatment of LyP.

85 12, we randomly assigned 329 patients to the brentuximab vedotin group (n=165) or the placebo group (

86 y was seen in 44 (67%) of 66 patients in the brentuximab vedotin group (n=21 grade 2, n=6 grade 3) an

87 e reported in 27 (41%) of 66 patients in the brentuximab vedotin group and 29 (47%) of 62 patients in

88 onths (95% CI 30.4-42.9) for patients in the brentuximab vedotin group compared with 24.1 months (11.

89 is, 28 (17%) of 167 patients had died in the brentuximab vedotin group compared with 25 (16%) of 160

90 as significantly improved in patients in the brentuximab vedotin group compared with those in the pla

91 The most frequent adverse events in the brentuximab vedotin group were peripheral sensory neurop

92 investigator to be treatment-related in the brentuximab vedotin group; no on-treatment deaths were r

93 Brentuximab vedotin has been evaluated as a bridge to al

94 Brentuximab vedotin has safely been combined with chemot

95 Brentuximab vedotin has shown significant clinical activ

96 t: pralatrexate, romidepsin, belinostat, and brentuximab vedotin have been approved for relapsed and

97 We aimed to assess whether brentuximab vedotin improves progression-free survival w

98 ng preclinical indications for evaluation of brentuximab vedotin in clinical studies of PEL patients.

99 stablish the maximum tolerated dose (MTD) of brentuximab vedotin in combination with ABVD and AVD.

100 abel, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD)

101 y reported excellent therapeutic efficacy of brentuximab vedotin in heavily pretreated CD30(+) malign

102 nt value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful clinical trial

103 ucted to evaluate the efficacy and safety of brentuximab vedotin in patients with relapsed or refract

104 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refract

105 dy results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory

106 phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory

107 are well aware of the incredible success of brentuximab vedotin in the treatment of patients with Ho

108 Brentuximab vedotin induced durable objective responses

109 Brentuximab vedotin induced objective responses in the m

110 Brentuximab vedotin induces an overall response rate of

111 The CD30-targeting antibody-conjugate brentuximab-vedotin inhibited proliferation in neoplasti

112 one dose of either 1.2 mg/kg or 1.8 mg/kg of brentuximab vedotin intravenously on day 1 of a 21 day c

113 Brentuximab vedotin is a monomethyl auristatin E-conjuga

114 The antibody drug conjugate brentuximab vedotin is a new, highly effective therapeut

115 Brentuximab vedotin is an anti-CD30 antibody-drug conjug

116 Brentuximab vedotin is an antibody-drug conjugate (ADC)

117 significant clinical efficacy, single-agent brentuximab vedotin is an approved treatment for relapse

118 Brentuximab vedotin is an effective treatment of relapse

119 The antibody drug conjugate brentuximab vedotin is associated with a high response r

120 Brentuximab vedotin is both active and well tolerated in

121 Brentuximab vedotin is currently approved for patients w

122 Brentuximab vedotin is effective in treating LyP (overal

123 The CD30-specific antibody-drug conjugate, brentuximab vedotin, is approved for the treatment of re

124 Patients received 1.2 or 1.8 mg/kg of brentuximab vedotin IV every 3 weeks (median, 8 cycles;

125 mic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatm

126 results demonstrate for the first time that brentuximab vedotin may serve as an effective therapy fo

127 Brentuximab vedotin monotherapy may provide a frontline

128 nts who achieved a complete response (CR) to brentuximab vedotin (N = 34) had estimated OS and PFS ra

129 ients received weekly infusions of 1.2 mg/kg brentuximab vedotin on days 1, 8, and 15 for two 28 day

130 % CI 60-86) patients were PET-positive after brentuximab vedotin; one PET-positive patient withdrew c

131 sequence, to receive 16 cycles of 1.8 mg/kg brentuximab vedotin or placebo intravenously every 3 wee

132 eceived any new treatment after single-agent brentuximab vedotin other than consolidative SCT.

133 showed no substantial age-related changes in brentuximab vedotin pharmacokinetics.

134 (7%) patients and diffuse rash at 1.2 mg/kg brentuximab vedotin plus 70 mg/m(2) of bendamustine in o

135 , including grade 4 neutropenia at 1.8 mg/kg brentuximab vedotin plus 80 mg/m(2) of bendamustine in t

136 is ongoing and will formally assess whether brentuximab vedotin plus AVD might redefine therapy in t

137 At present, a phase 3 trial comparing brentuximab vedotin plus AVD to ABVD alone is ongoing an

138 ed pulmonary toxic effects when treated with brentuximab vedotin plus AVD.

139 ase 2, all patients were assigned to receive brentuximab vedotin plus bendamustine at the recommended

140 and clinical activity of the combination of brentuximab vedotin plus bendamustine in heavily pretrea

141 INTERPRETATION: This study shows that brentuximab vedotin plus bendamustine, with a favourable

142 Moreover, brentuximab-vedotin produced apoptosis in all CD30(+) MC

143 Furthermore, in vivo brentuximab vedotin promoted tumor regression and prolon

144 s with persistent abnormalities on PET after brentuximab vedotin received augICE; however, all patien

145 AFM13 was also active in brentuximab vedotin-refractory patients.

146 Brentuximab vedotin represents one such ADC that has rec

147 Brentuximab vedotin (SGN-35) is an anti-CD30 monoclonal

148 The CD30-targeting Ab-drug conjugate brentuximab vedotin (SGN-35) was recently approved for t

149 inker, producing the antibody-drug conjugate brentuximab vedotin (SGN-35).

150 Brentuximab vedotin should not be given with bleomycin i

151 In summary, brentuximab vedotin showed antitumor activity in patient

152 In addition, brentuximab-vedotin suppressed the engraftment of MCPV-1

153 and thus may serve as potential targets for brentuximab vedotin therapy.

154 valuable tool in optimizing patient-specific brentuximab vedotin treatment regimens.

155 After completion of brentuximab vedotin treatment, patients received a PET s

156 4 months was 56.3% (36 of 64 patients) with brentuximab vedotin versus 12.5% (eight of 64) with phys

157 We aimed to assess efficacy and safety of brentuximab vedotin versus conventional therapy for prev

158 onse lasting at least 4 months was seen with brentuximab vedotin versus physician's choice of methotr

159 The ADC brentuximab vedotin was associated with manageable toxic

160 Overall, significant activity with brentuximab vedotin was observed in relapsed/refractory

161 Brentuximab vedotin was well tolerated and associated wi

162 Furthermore, brentuximab-vedotin was found to downregulate anti-IgE-i

163 The extended use of brentuximab-vedotin was reported for CD30(+) nonanaplast

164 The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was n

165 s in the therapeutic antibody-drug conjugate brentuximab vedotin, which displays a heterogeneous drug

166 The use of new drugs such as brentuximab vedotin will hopefully further increase the

167 Incorporating brentuximab vedotin with frontline regimens is currently

168 The combination of brentuximab vedotin with rituximab was generally well to

169 ts who achieved a complete remission (CR) on brentuximab vedotin, with estimated 3-year overall survi